Silverstein William K, Noda Yoshihiro, Barr Mera S, Vila-Rodriguez Fidel, Rajji Tarek K, Fitzgerald Paul B, Downar Jonathan, Mulsant Benoit H, Vigod Simone, Daskalakis Zafiris J, Blumberger Daniel M
Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Depress Anxiety. 2015 Dec;32(12):871-91. doi: 10.1002/da.22424. Epub 2015 Sep 18.
A significant proportion of patients with depression fail to respond to psychotherapy and standard pharmacotherapy, leading to treatment-resistant depression (TRD). Due to the significant prevalence of TRD, alternative therapies for depression have emerged as viable treatments in the armamentarium for this disorder. Repetitive transcranial magnetic stimulation (rTMS) is now being offered in clinical practice in broader numbers. Many studies have investigated various different neurobiological predictors of response of rTMS. However, a synthesis of this literature and an understanding of what biological targets predict response is lacking. This review aims to systematically synthesize the literature on the neurobiological predictors of rTMS in patients with depression.
Medline (1996-2014), Embase (1980-2014), and PsycINFO (1806-2014) were searched under set terms. Two authors reviewed each article and came to consensus on the inclusion and exclusion criteria. All eligible studies were reviewed, duplicates were removed, and data were extracted individually.
The search identified 1,673 articles, 41 of which met both inclusion and exclusion criteria. Various biological factors at baseline appear to predict response to rTMS, including levels of certain molecular factors, blood flow in brain regions implicated in depression, electrophysiological findings, and specific genetic polymorphisms.
Significant methodological variability in rTMS treatment protocols limits the ability to generalize conclusions. However, response to treatment may be predicted by baseline frontal lobe blood flow, and presence of polymorphisms of the 5-hydroxytryptamine (5-HT) -1a gene, the LL genotype of the serotonin transporter linked polymorphic region (5-HTTLPR) gene, and Val/Val homozygotes of the brain-derived neurotrophic factor (BDNF) gene.
相当一部分抑郁症患者对心理治疗和标准药物治疗无反应,导致难治性抑郁症(TRD)。由于TRD的患病率较高,抑郁症的替代疗法已成为该疾病治疗手段中的可行治疗方法。重复经颅磁刺激(rTMS)目前在临床实践中的应用越来越广泛。许多研究调查了rTMS反应的各种不同神经生物学预测因素。然而,缺乏对该文献的综合以及对预测反应的生物学靶点的理解。本综述旨在系统地综合关于抑郁症患者rTMS神经生物学预测因素的文献。
按照设定的术语在Medline(1996 - 2014年)、Embase(1980 - 2014年)和PsycINFO(1806 - 2014年)中进行检索。两位作者对每篇文章进行评审,并就纳入和排除标准达成共识。对所有符合条件的研究进行评审,去除重复项,并分别提取数据。
检索到1673篇文章,其中41篇符合纳入和排除标准。基线时的各种生物学因素似乎可预测对rTMS的反应,包括某些分子因素的水平、与抑郁症相关脑区的血流、电生理结果以及特定的基因多态性。
rTMS治疗方案中存在显著的方法学差异,限制了结论的推广能力。然而,治疗反应可能由基线额叶血流、5 - 羟色胺(5 - HT)-1a基因多态性、血清素转运体连接多态性区域(5 - HTTLPR)基因的LL基因型以及脑源性神经营养因子(BDNF)基因的Val/Val纯合子预测。